Rolvedon (eflapegrastim-xnst) — Medica

Initial criteria

• Patient age ≥ 18 years
• AND Patient meets ONE of the following:
• i. Receiving myelosuppressive anti-cancer medications associated with a high risk of febrile neutropenia (≥ 20% based on the chemotherapy regimen)
• OR ii. Receiving myelosuppressive anti-cancer medications associated with < 20% risk of febrile neutropenia AND has at least one risk factor for febrile neutropenia (e.g., age ≥ 65 years, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver and/or renal dysfunction, poor performance status, or HIV infection)
• OR iii. Had a neutropenic complication from prior chemotherapy without prior colony stimulating factor prophylaxis AND a reduced dose or frequency of chemotherapy may compromise treatment outcome
• AND Prescribed by or in consultation with an oncologist or hematologist

Approval duration

6 months